Use of dipyridamole protects hospital healthcare staff against COVID-19 infections.

Key Messages

Healthcare workers in hospitals have a very high risk of contracting SARS-CoV-2 infection and developing COVID‐19.

This study followed 33 health-care workers. Fourteen workers were taking dipyridamole as a preventive drug in addition to using standard preventative methods compared to 19 workers also using standard preventative methods, but not taking dipyridamole.

Out of 14 staff members who took dipyridamole, five (35.7%) contracted COVID-19 and four of the five developed interstitial pneumonia. Among the group of 19 employees who did not take dipyridamole, 13 (68.4%) contracted COVID-19 and 11 of the 13 developed interstitial pneumonia.

The study concludes taking dipyridamole provides significant protection against infection from SARS-CoV-2, and helps to prevent COVID-19.

Тромбоз, гемостаз и реология

Publication Date: December 8, 2020
Peer Reviewed: Yes
Publication Type: Original | Clinical Prospective
DOI: https://www.doi.org/10.25555/THR.2020.4.0947

The opportunity of dipyridamole using for nonspecific primary prophylaxis against the COVID‐19 infection in healthcare staff

И.В. Куртов, Ю.О. Берман, Н.А. Никулина, Ю.В. Кузнецова, И.Л. Давыдкин

Abstract

Summary. Background. Healthcare workers are under high risk of the novel coronavirus infection COVID‐19. Objectives: to show the opportunity of dipyridamole using within the set of primary prophylaxis measures against the infection of COVID‐19. Patients/Methods. We followed up 33 people from medical staff, of them 14 were taking dipyridamole in addition to standard prophylaxis methods; the comparison group consisted of 19 people who did not take dipyridamole. Results. Despite standard prophylaxis in a multidisciplinary hospital, out of 14 staff members who took dipyridamole, 5 (35.7%) catch coronavirus infection COVID‐19 (justified); interstitial pneumonia was diagnosed in 4 people. In a group of 19 employees who did not take dipyridamole, 13 (68.4%) fell ill; interstitial pneumonia was diagnosed in 11 people. Conclusions. The opportunity of dipyridamole using has been shown as an additional means to reduce the risk to infect with COVID‐19.